Dapagliflozin in type 2 diabetes: effectiveness across the spectrum of disease and over time

Publisher： John Wiley & Sons Inc

E-ISSN： 1742-1241|69|2|186-198

ISSN： 1368-5031

Source： INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol.69, Iss.2, 2015-02, pp. : 186-198

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The cost‐effectiveness of dapagliflozin versus sulfonylurea as an add‐on to metformin in the treatment of Type 2 diabetes mellitus

By  

DIABETIC MEDICINE, Vol. 32, Iss. 7, 2015-07 ,pp. : 890-898

John Wiley & Sons Inc

Access to resources Recommend Favorite

Durability and tolerability of dapagliflozin over 52 weeks as add‐on to metformin and sulphonylurea in type 2 diabetes

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 11, 2015-11 ,pp. : 1075-1084

John Wiley & Sons Inc

Access to resources Recommend Favorite

Association of postprandial and fasting plasma glucose with HbA1c across the spectrum of glycaemic impairment in type 2 diabetes

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 71, Iss. 12, 2017-12 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double‐blind placebo‐controlled 102‐week trial

By  

DIABETIC MEDICINE, Vol. 32, Iss. 4, 2015-04 ,pp. : 531-541

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in weight loss‐related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin

By  

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 16, Iss. 7, 2014-07 ,pp. : 645-650

John Wiley & Sons Inc

Access to resources Recommend Favorite